In 2019, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in these same therapy areas totaled approximately $8.5 billion. Throughout our 2019-2029 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.

Table of contents

  • Biosimilars - Market Events And Forecast - Overview Of Biosimilars Forecasts
    • Overview of Biosimilar Forecasts
      • Key Drivers and Barriers to Biosimilars in the Major Markets
      • Total Major-Market Reference Brand and Biosimilar Market Shares: 2029
      • Total Major-Market Reference Brand and Biosimilar Market Shares
      • Biosimilar Erosion
        • Example of the Erosion of Biologics' Uptake by Biosimilar Competition
    • Biosimilar Erosion in the Major Markets
      • Biosimilar Erosion in the Major Markets: 2019, 2024, 2029
      • Total Major-Market Reference-Brand and Biosimilar Sales: 2019-2029
      • Definitions
      • Biosimilar and Reference-Brand Sales and Total Market Savings in the Major Markets: 2019-2029
      • U.S. Sales of Reference Brands and Biosimilars: 2019-2029
      • Order of Biosimilar Entry: United States
      • EU5 Sales of Reference Brands and Biosimilars: 2019-2029
      • Order of Biosimilar Entry: EU5
      • Japanese Sales of Reference Brands and Biosimilars: 2019-2029
      • Order of Biosimilar Entry: Japan
      • Major-Market Sales of Reference Brands and Biosimilars: 2019-2029
      • Sales Erosion of Major-Market Reference Brands: 2019-2029
      • Major-Market Share of Biosimilars by Region: 2019-2029
      • Major-Market Shares of Biosimilars by Class: 2019-2029

Author(s): Hamzah Aideed, M.Sc.; Yashu Malhotra

Hamzah Aideed, M.Sc., is a principal analyst on the Biosimilars team at DRG, part of Clarivate. He conducts primary and secondary market research to provide in-depth analysis and insight into the biopharmaceutical industry. Prior to joining DRG, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.

Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Onkos teams at DRG, part of Clarivate. Prior to joining DRG, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.